Patents Assigned to Calitor Sciences, LLC
-
Patent number: 10751339Abstract: The invention relates to the preparation and use of new aminopyrimidine derivatives as drug candidates in free form or in pharmaceutically acceptable salt form and formulations thereof for the modulation of a disorder or disease which is mediated by the activity of the PI3K enzymes. The invention also provides pharmaceutically acceptable compositions comprising such compounds and methods of using the compositions in the treatment of disorders or diseases, such as disorders of immunity and inflammation in which PI3K enzymes play a role in leukocyte function, and hyperproliferative disorders associated with PI3K activity, including but not restricted to leukemias and solid tumors, in mammals, especially humans.Type: GrantFiled: January 18, 2019Date of Patent: August 25, 2020Assignees: SUNSHINE LAKE PHARMA CO., LTD., CALITOR SCIENCES, LLCInventors: Ning Xi, Liang Wang, Xuejin Feng, Min Liao
-
Publication number: 20200222376Abstract: The present invention provides salts of pyrazolo[1,5-?]pyridine derivative and use thereof. The invention also relates to a pharmaceutically acceptable composition comprising such salts and a method of using the salts and the pharmaceutically acceptable composition to prevent or treat a proliferative disorder or pulmonary fibrosis in a patient.Type: ApplicationFiled: December 15, 2018Publication date: July 16, 2020Applicants: Sunshine Lake Pharma Co., Ltd., Calitor Sciences, LLCInventors: Ning Xi, Mingming Sun
-
Patent number: 10683297Abstract: The present invention provides novel heteroaryl compounds, pharmaceutical acceptable salts and formulations thereof. They are useful in preventing, managing, treating or lessening the severity of a protein kinase-mediated disease. The invention also provides pharmaceutically acceptable compositions comprising such compounds and methods of using the compositions in the treatment of protein kinase-mediated disease.Type: GrantFiled: November 10, 2018Date of Patent: June 16, 2020Assignees: CALITOR SCIENCES, LLC, NORTH & SOUTH BROTHER PHARMACY INVESTMENT COMPANY LIMITEDInventors: Ning Xi, Minxiong Li, Ju Peng, Xiaobo Li, Tao Zhang, Haiyang Hu, Wuhong Chen, Changlin Bai, Donghua Ke, Peng Chen
-
Publication number: 20190224197Abstract: The invention relates to the preparation and use of new aminopyrirnidine derivatives as drug candidates in free form or in pharmaceutically acceptable salt form and formulations thereof for the modulation of a disorder or disease which is mediated by the activity of the PI3K enzymes The invention also provides pharmaceutically acceptable compositions comprising such compounds and methods of using the compositions in the treatment of disorders or diseases, such as disorders of immunity and inflammation in which PI3K enzymes play a role in leukocyte function, and hyperproliferative disorders associated with PI3K activity, including but not restricted to leukemias and solid tumors, in mammals, especially humans.Type: ApplicationFiled: January 18, 2019Publication date: July 25, 2019Applicants: Sunshine Lake Pharma Co., Ltd., Calitor Sciences, LLCInventors: Ning Xi, Liang Wang, Xuejin Feng, Min Liao
-
Patent number: 10266521Abstract: The present invention provides novel heteroaryl compounds, pharmaceutical acceptable salts and formulations thereof. They are useful in preventing, managing, treating or lessening the severity of a protein kinase-mediated disease. The invention also provides pharmaceutically acceptable compositions comprising such compounds and methods of using the compositions in the treatment of protein kinase-mediated disease.Type: GrantFiled: January 4, 2018Date of Patent: April 23, 2019Assignees: CALITOR SCIENCES, LLC, SUNSHINE LAKE PHARMA CO., LTD.Inventors: Ning Xi, Minxiong Li, Xiaobo Li, Wuhong Chen, Tao Zhang, Haiyang Hu, Weilong Dai, Yanjun Wu
-
Patent number: 10059689Abstract: The present invention provides novel heteroaryl compounds, pharmaceutical acceptable salts and formulations thereof useful in preventing, managing, treating or lessening the severity of a protein kinase-mediated disease. The invention also provides pharmaceutically acceptable compositions comprising such compounds and methods of using the compositions in the treatment of protein kinase-mediated disease.Type: GrantFiled: October 10, 2015Date of Patent: August 28, 2018Assignees: CALITOR SCIENCES, LLC, SUNSHINE LAKE PHARMA CO., LTD.Inventors: Ning Xi, Minxiong Li, Xiaobo Li, Weilong Dai, Haiyang Hu, Tao Zhang, Wuhong Chen
-
Publication number: 20180162841Abstract: The present invention provides novel heteroaryl compounds, pharmaceutical acceptable salts and formulations thereof. They are useful in preventing, managing, treating or lessening the severity of a protein kinase-mediated disease. The invention also provides pharmaceutically acceptable compositions comprising such compounds and methods of using the compositions in the treatment of protein kinase-mediated disease.Type: ApplicationFiled: January 4, 2018Publication date: June 14, 2018Applicants: Sunshine Lake Pharma Co., Ltd., Calitor Sciences, LLCInventors: Ning Xi, Minxiong Li, Xiaobo Li, Wuhong Chen, Tao Zhang, Haiyang Hu, Weilong Dai, Yanjun Wu
-
Patent number: 9957233Abstract: The invention relates to a process for preparing substituted quinolin-4-ol compounds useful for preparing protein tyrosine kinase (PTK) inhibitors which are useful in treating cancer.Type: GrantFiled: August 2, 2017Date of Patent: May 1, 2018Assignees: CALITOR SCIENCES, LLC, SUNSHIRE LAKE PHARMA CO., LTD.Inventor: Ning Xi
-
Patent number: 9938257Abstract: The present invention provides novel heteroaryl compounds, pharmaceutical acceptable salts and formulations thereof. They are useful in preventing, managing, treating or lessening the severity of a protein kinase-mediated disease. The invention also provides pharmaceutically acceptable compositions comprising such compounds and methods of using the compositions in the treatment of protein kinase-mediated disease.Type: GrantFiled: September 7, 2016Date of Patent: April 10, 2018Assignees: CALITOR SCIENCES, LLC, SUNSHINE LAKE PHARMA CO., LTD.Inventors: Ning Xi, Minxiong Li, Xiaobo Li, Wuhong Chen, Tao Zhang, Haiyang Hu, Weilong Dai, Yanjun Wu
-
Patent number: 9926324Abstract: The present invention provides heteroaromatic derivatives and pharmaceutical acceptable salts and formulations thereof useful in modulating the protein kinase activity, especially phosphatidylinositol 3-kinases (PI3 kinases) and mTOR, and in modulating inter- and/or intra-cellular signaling activities such as proliferation, differentiation, apoptosis, migration and invasion. The invention also provides pharmaceutically acceptable compositions comprising such compounds and methods of using the compositions in the treatment of hyperproliferative disorders in mammals, especially humans.Type: GrantFiled: November 10, 2013Date of Patent: March 27, 2018Assignees: CALITOR SCIENCES, LLC, SUNSHINE LAKE PHARMA CO., LTD.Inventor: Ning Xi
-
Patent number: 9920033Abstract: The present invention relates to a crystalline form of N-(3-fluoro-4-((7-(2-hydroxy-2-methylpropoxy)quinolin-4-yl)oxy)phenyl)-1,5-dimethyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazole-4-carboxamide p-toluenesulfonate, the process for preparing the crystalline form thereof, and the pharmaceutical compositions comprising the crystalline form thereof. This invention also relates to a method of using such a crystalline form and pharmaceutical compositions comprising the crystalline form thereof in the treatment of hyperproliferative diseases in mammals, especially in humans.Type: GrantFiled: November 12, 2016Date of Patent: March 20, 2018Assignees: Calitor Sciences, LLC, Sunshine Lake Pharma Co., LTD.Inventors: Ning Xi, Mingming Sun
-
Publication number: 20170313678Abstract: The present invention relates to a crystalline form of N-(3-fluoro-4-((7-(2-hydroxy-2-methylpropoxy)quinolin-4-yl)oxy)phenyl)-1,5-dimethyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazole-4-carboxamide p-toluenesulfonate, the process for preparing the crystalline form thereof, and the pharmaceutical compositions comprising the crystalline form thereof. This invention also relates to a method of using such a crystalline form and pharmaceutical compositions comprising the crystalline form thereof in the treatment of hyperproliferative diseases in mammals, especially in humans.Type: ApplicationFiled: November 12, 2016Publication date: November 2, 2017Applicants: Sunshine Lake Pharma Co., Ltd., Calitor Sciences, LLCInventors: Ning Xi, Mingming Sun
-
Patent number: 9718841Abstract: The present invention provides substituted bicyclic pyrazolone compounds, which are used to inhibit or modulate the activity of receptor tyrosine kinases, especially Axl, Mer, c-Met and Ron. The invention also provides pharmaceutical compositions comprising the compound disclosed herein, and a method of preventing, treating or lessening the severity of a proliferative disorder in a patient with the compounds or the pharmaceutical compositions disclosed herein.Type: GrantFiled: April 16, 2015Date of Patent: August 1, 2017Assignees: CALITOR SCIENCES, LLC, SUNSHINE LAKE PHARMA CO., LTD.Inventors: Ning Xi, Yanjun Wu
-
Patent number: 9695150Abstract: The present invention relates to a crystalline form of N-(3-fluoro-4-((7-(2-hydroxy-2-methylpropoxy)quinolin-4-yl)oxy)phenyl)-1,5-dimethyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazole-4-carboxamide p-toluenesulfonate, the process for preparing the crystalline form thereof, and pharmaceutical compositions comprising the crystalline form thereof. This invention also relates to a method of using such a crystalline form in the treatment of hyperproliferative diseases in mammals, especially in humans.Type: GrantFiled: November 12, 2016Date of Patent: July 4, 2017Assignees: CALITOR SCIENCES, LLC, SUNSHINE LAKE PHARMA CO., LTD.Inventors: Ning Xi, Mingming Sun
-
Publication number: 20170183358Abstract: The present invention provides substituted bicyclic pyrazolone compounds, which are used to inhibit or modulate the activity of receptor tyrosine kinases, especially Axl, Mer, c-Met and Ron. The invention also provides pharmaceutical compositions comprising the compound disclosed herein, and a method of preventing, treating or lessening the severity of a proliferative disorder in a patient with the compounds or the pharmaceutical compositions disclosed herein.Type: ApplicationFiled: April 16, 2015Publication date: June 29, 2017Applicants: CALITOR SCIENCES, LLC, SUNSHINE LAKE PHARMA CO., LTD.Inventors: Ning Xi, Yanjun WU
-
Patent number: 9670194Abstract: The invention relates to the preparation and use of new aminopyrimidine derivatives as drug candidates in free form or in pharmaceutically acceptable salt form and formulations thereof for the modulation of a disorder or disease which is mediated by the activity of the PI3K enzymes. The invention also provides pharmaceutically acceptable compositions comprising such compounds and methods of using the compositions in the treatment of disorders or diseases, such as disorders of immunity and inflammation in which PI3K enzymes play a role in leukocyte function, and hyperproliferative disorders associated with PI3K activity, including but not limited to leukemias and solid tumors, in mammals, especially humans.Type: GrantFiled: September 17, 2014Date of Patent: June 6, 2017Assignees: CALITOR SCIENCES, LLC, SUNSHINE LAKE PHARMA CO., LTD.Inventors: Ning Xi, Liang Wang, Zuping Wu, Xuejin Feng, Yanjun Wu
-
Patent number: 9657007Abstract: The invention relates to the preparation and use of new aminopyrimidine derivatives as drug candidates in free form or in pharmaceutically acceptable salt form and formulations thereof for the modulation of a disorder or disease which is mediated by the activity of the PI3K enzymes. The invention also provides pharmaceutically acceptable compositions comprising such compounds and methods of using the compositions in the treatment of disorders or diseases, such as disorders of immunity and inflammation in which PI3K enzymes play a role in leukocyte function, and hyperproliferative disorders associated with PI3K activity, including but not restricted to leukemias and solid tumors, in mammals, especially humans.Type: GrantFiled: September 17, 2014Date of Patent: May 23, 2017Assignees: CALITOR SCIENCES, LLC, SUNSHINE LAKE PHARMA CO., LTD.Inventors: Ning Xi, Liang Wang, Tingjin Wang
-
Publication number: 20170137404Abstract: The present invention relates to a crystalline form of N-(3-fluoro-4-((7-(2-hydroxy-2-methylpropoxy)quinolin-4-yl)oxy)phenyl)-1,5-dimethyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazole-4-carboxamide p-toluenesulfonate, the process for preparing the crystalline form thereof, and pharmaceutical compositions comprising the crystalline form thereof. This invention also relates to a method of using such a crystalline form in the treatment of hyperproliferative diseases in mammals, especially in humans.Type: ApplicationFiled: November 12, 2016Publication date: May 18, 2017Applicants: Sunshine Lake Pharma Co., Ltd., Calitor Sciences, LLCInventors: Ning Xi, Mingming Sun
-
Publication number: 20170081338Abstract: The present invention provides novel heteroaryl compounds, pharmaceutical acceptable salts and formulations thereof. They are useful in preventing, managing, treating or lessening the severity of a protein kinase-mediated disease. The invention also provides pharmaceutically acceptable compositions comprising such compounds and methods of using the compositions in the treatment of protein kinase-mediated disease.Type: ApplicationFiled: September 13, 2016Publication date: March 23, 2017Applicants: Sunshine Lake Pharma Co., Ltd., Calitor Sciences, LLCInventors: Ning Xi, Weilong Dai, Minxiong Li, Wuhong Chen, Tao Zhang, Haiyang Hu, Xiaobo Li, Jun Liu, Tingjin Wang
-
Patent number: 9598400Abstract: The present invention provides novel substituted quinoline compounds, pharmaceutical acceptable salts and formulations thereof useful in modulating the protein tyrosine kinase activity, and in modulating cellular activities such as proliferation, differentiation, apoptosis, migration and invasion. The invention also provides pharmaceutically acceptable compositions comprising such compounds and methods of using the compositions in the treatment of hyperproliferative disorders in mammals, especially humans.Type: GrantFiled: August 12, 2015Date of Patent: March 21, 2017Assignees: CALITOR SCIENCES, LLC, SUNSHINE LAKE PHARMA CO., LTD.Inventor: Ning Xi